Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).

Jianhua SHI; Ying CHENG; Qiming WANG; Kai LI; Lin WU; Baohui HAN; Gongyan CHEN; Jianxing HE; Jie WANG; Haifeng QIN; Xiaoling LI

Return

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).

Author: Jianhua SHI ¹ ; Ying CHENG ² ; Qiming WANG ³ ; Kai LI ⁴ ; Lin WU ⁵ ; Baohui HAN ⁶ ; Gongyan CHEN ⁷ ; Jianxing HE ⁸ ; Jie WANG ⁹ ; Haifeng QIN ¹⁰ ; Xiaoling LI ¹¹
Author Information

1. Department of Medical Oncology, Linyi Cancer Hospital, Linyi, 276002, China.
2. Department of Thoracic Medical Oncology, Jilin Cancer Hospital, Changchun, 130012, China. jl.cheng@163.com.
3. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450003, China.
4. Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
5. Department of Thoracic Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University (Hunan Cancer Hospital), Changsha, 410031, China.
6. Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China.
7. Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
8. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
9. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
10. Department of Pulmonary Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, 100039, China.
11. Department of Medical Oncology, Liaoning Cancer Hospital, Shenyang, 110042, China.
Publication Type:Journal Article
Keywords: anlotinib; chemotherapy; short-term relapsed; small-cell lung cancer
MeSH: Humans; Lung Neoplasms/drug therapy*; Treatment Outcome; Neoplasm Recurrence, Local/chemically induced*; Quinolines/adverse effects*
From: Frontiers of Medicine 2022;16(5):766-772
CountryChina
Language:English
Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing ⩾ two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gammaglutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.